Question · asked by 1 review
Casirivimab/imdevimab vs placebo: Grades 3 and 4 adverse events
- Population
- non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
- Intervention
- Casirivimab/imdevimab
- Comparison
- placebo
- Outcome
- Grades 3 and 4 adverse events
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Casirivimab/imdevimab vs placebo Adverse events: grade 3‐4 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease) The review found no eligible studies for this question. SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 (2021) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Casirivimab/imdevimab vs placebo · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to… · 1 review
- Casirivimab/imdevimab vs usual care · hospitalised individuals with COVID‐19 (moderate to severe disease) · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.